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Abstract: Background: Glioblastomas (GBMs) are classified into isocitrate dehydrogenase (IDH)
mutants and IDH wild-types (IDH-wt). This study aimed at identifying the mutational assets of
IDH-wt GBMs in patients aged 18–54 years for which limited data are available. Methods: Sixteen
IDH-wt GBMs from adults < 55 years old were explored for mutations, copy number variations,
tumour mutational load (TML), and mutational spectrum by a 409 genes TML panel. Results: Eight
(50%) IDH-wt GBMs were hypermutated (TML > 9 mutations/Mb) and two (12.5%) were ultra-mutated
(TML > 100 mutations/Mb). One ultra-mutated GBM had microsatellite instability (MSI), a somatic
MSH6 mutation, and a germline POLE mutation. The other ultra-mutated GBMs had MSI and two
somatic mutations in MSH2. Both ultra-mutated GBMs featured at least 25% giant cells. The overall
survival of eight patients with hypermutated GBMs was significantly longer than that of patients with
non-hypermutated GBMs (p = 0.04). Conclusions: We identified a hyper-mutated subgroup among
IDH-wt GBMs in adults < 55 years that had improved prognosis. Two cases were ultra-mutated
and characterized by the presence of at least 25% giant cells, MMR mutations, and MSI. Since high
TML has been associated with response to immune checkpoint inhibition in paediatric gliomas, the
identification of a subtype of ultra-mutated IDH-wt GBM may have implications for immunotherapy.
Keywords: glioblastoma; IDH wild-type; giant cells; mismatch repair; POLE; tumour mutation load
1. Introduction
Glioblastoma (GBM) is the most common malignant primary tumour of the central nervous
system in adults [1]. The standard of care for patients affected by GBM is maximal safe surgical
resection, followed by chemotherapy with temozolomide and radiotherapy [2,3]. However, despite
treatment, most GBM patients undergo recurrence and die within 15–18 months of diagnosis, while
only about 5% survive more than 5 years [1].
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The 2016 World Health Organization (WHO) classification subdivides GBM into isocitrate
dehydrogenase (IDH) mutant and IDH wild-type (wt), based on the mutational status of IDH1/IDH2
genes [4]. This distinction is prognostically relevant. Patients with IDH-mutant GBM have significantly
longer overall and recurrence-free survival compared with patients with IDH-wt GBM [4–6]. Moreover,
these two types of GBM have different age distributions and pathogenesis.
The IDH-mutant GBM is more frequent in younger patients (< 55 years, median: 45 years) and is
considered to be secondary, i.e., derived from the progression of low-grade astrocytoma. In addition, it
is characterized by frequent mutations in the ATRX and TP53 genes [4].
The IDH-wt GBM mainly affects older subjects (> 55 years, median: 62 years) [7] and is considered
primary, i.e., arises de novo. From a molecular standpoint, IDH-wt GBM is defined by the absence of
IDH mutations and may have different genetic alterations. Among those, EGFR amplification is the
most frequent (35–45%), followed by PTEN mutations/deletions and CDKN2A deletions [8–11].
In a recent study, about 25% of GBMs, and mainly IDH-wt ones, displayed microsatellite instability
(MSI) [12]. This is a condition of genetic hypermutability resulting from defective DNA mismatch
repair (MMR) and characterized by clustering of mutations in highly repetitive short DNA sequences,
called microsatellites [13]. Microsatellite instability is a marker of defective MMR [12], which is mostly
found in recurrent GBMs as a result of treatment [14].
As IDH-wt GBM has the lowest incidence between 18 and 55 years, most studies on IDH-wt GBM
focused on either paediatric age or patients above 55 years [5,9,15–19]. Thus, the mutational spectrum
of IDH-wt GBM has not been specifically investigated in adults between 18 and 54 years of age.
This study aimed to identify the mutational spectrum of IDH-wt GBMs from adult patients
younger than 55 years, exploring mutations and copy number variations of 409 genes as well as tumour
mutational load and mutational signatures.
2. Results
2.1. Clinico-pathological Features
Our cohort of IDH-wt GBMs included 16 cases out of 108 (14.8%) consecutive GBMs that had
been diagnosed in patients < 55 years in a single hospital. The cohort comprised 5 female and 11 male
patients (mean age 38.3 years; range: 18–49 years) (Table 1).
One patient (case 5 GL) had a breast ductal carcinoma seven years before the occurrence of
GBM. Brain metastatic carcinoma was excluded by immunohistochemistry with anti-GFAP and
anti-cytokeratins antibodies. No other patient had or developed other tumours during follow-up.
One patient (case 4 GL) had a family history (one brother) positive for GBM. The overall survival of
the patients ranged between 1 and 79 months (median: 23.5 months; mean: 28.7 months).
At histopathology, one tumour (15 GL) was an epithelioid GBM (as defined by the presence of
a dominant population of closely packed epithelioid cells) [10], one (5 GL) was a giant cell GBM (as
defined by the presence of dominant bizarre multinucleated giant cells) [10], and three additional cases
(1 GL, 3 GL, 12 GL) contained at least 25% multinucleated giant cells (Figure 1). In detail, in cases
1 GL, 3 GL, and 12 GL, giant cells (respectively accounting for 50%, 50%, and 25% of the tumour cells)
were homogeneously distributed and intermingled with mononuclear tumour cells with milder atypia.
Cases 9 GL and 16 GL also had giant cells representing less than 10% of cancer cells.
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Table 1. Clinico-pathological features and main molecular data of 16 IDH-wt GBMS in adult patients younger than 55 years. Cases are ordered by increasing TML.
Case Gender Age Site OS(months) IDH1/2 EGFR ATRX TP53 PTEN TML MMR Genes
4 GL M 49 fronto-temporal right DOD (11) wt ampl 5.28
6 GL M 41 fronto-temporal right DOD (3) wt ampl 5.66
2 GL F 49 temporo-parietal left DOD (46) wt ampl/mut 6.34
15 GL M 43 fronto-basal DOD (14) wt mut 6.47
16 GL M 40 temporal left DOD (9) wt mut 7.12
7 GL M 39 temporo-parieto-occipital left DOD (14) wt ampl 7.33
13 GL F 41 temporal left Alive (24) wt ampl 7.75
9 GL M 18 temporo-parietal left Alive (38) wt mut mut 8.22
11 GL F 29 cerebellar right DOD (15) wt 9.24
10 GL M 43 frontal DOD (15) wt mut mut 10.1
8 GL M 46 temporo-parietal left Alive (41) wt mut 12.35
1 GL F 47 temporo-parieto-occipital right Alive (23) wt mut mut 13.07 MLH1 mut *
14 GL M 43 frontal lobe Alive (14) wt mut 14.34
3 GL M 24 temporal left Alive (24) wt ampl/mut mut 43.19
12 GL M 39 frontal Alive (32) wt mut mut 168.02 MSH6 mut
5 GL F 37 frontal Alive (79) wt mut mut 219.79 MSH2 mut
OS: overall survival. DOD: died of disease. TML: tumour mutation load. MMR: mismatch repair. F: female. M: male. Ampl: amplified. Mut: mutation. * Classified as benign in the
PolyPhen Database.
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2.2. Mutational Status of 409 Genes
All 16 cases were analysed for 409 genes included in the TML assay panel (ThermoFisher,
Waltham, MA, USA). Sequencing achieved an average coverage of 282× (36×–712×) in tumours and
236× (26×–651×) in normal samples (Supplementary Materials Table S1). All cases were confirmed to be
IDH1/2 wild-type. Mutations were found in at least one gene in 13 of the 16 cases, while three samples
(7 GL, 11 GL, 13 GL) had no mutation in any of the 409 genes analysed (Figure 2, Supplementary
Materials Table S2). Those latter cases had only mutations in untranslated regions. A total of 45
mutations in 29 genes were identified, including 19 missense, 16 nonsense, 7 frameshift, and 3 splice
site alterations (Supplementary Materials Table S2).
The most frequent inactivating somatic mutations involved TP53 (7/16; 43.8%) and PTEN (6/16;
37.5%) genes, followed by MMR genes that were found altered in 3 GBMs: case 1 GL had a missense
Ser193Leu mutation in MLH1 that is classified as benign in PolyPhen database, case 5 GL had two
MSH2 mutations including a truncating Val684Ter and a missense Gly164Glu mutation, case 12 GL
had a truncating Glu1322Ter mutation in MSH6. The EGFR activating Arg108Lys mutation was found
in two cases (2 GL and 3 GL). A truncating Glu1365Ter mutation in the ATRX gene was found in one
case (12 GL). A BRAF Val600Glu mutation was observed in the epithelioid GBM 15 GL. An FGFR1
pathogenic missense Lys687Asp mutation was seen in case 14 GL.
Germline heterozygous mutations were found in three patients, comprising the MUTYH
Gly396Asp (rs36053993) in patients 6 GL and 12 GL and a stop-gain (Glu265Ter) in RNASEL (rs74315364)
in patient 2 GL (Figure 1).
2.3. Gene and Chromosomal Copy Number Alterations
The CNV status was estimated for all 409 genes using sequencing data. Four genes had focal
amplification: EGFR in 6/16 cases (37.5%), CCNE1, CDK4, and MDM2 in 1 case each (6.3%). Two genes
showed homozygous deletion: CDKN2A in 5/16 cases (31.3%) and RB1 in 3/16 cases RB1 in 3/16
cases. Based on the chromosomal position of each gene, the status of chromosome arms was inferred
(Figure 3). The major alterations were gains in chromosome 7 (14/16; 87.5%) and losses in chromosomes
10 (6/16; 37.5%), 13 (12/16; 75.0%), and in 19q arm (11/16; 68.8%). Frequent homozygous deletions were
detected in chromosome 19 and involved loci of BCL3, CIC, and MARK4 genes (6/16; 37.5%).
2.4. Tumour Mutational Load
The number of mutations/Mb in the 16 GBMs ranged from 5.28 to 219.79 (median 8.73) (Figure 2,
Table 1); 8 of the 16 cases (1 GL, 3 GL, 5 GL, 8 GL, 10 GL, 11 GL, 12 GL, 14 GL) had > 9 muts/Mb and
were considered hypermutated; 2 of these (5 GL and 12 GL) had > 100 muts/Mb and were considered
ultra-mutated according to Campbell et al. [20].
2.5. Mutational Spectrum
The mutational spectrum of our IDH-wt cohort was characterized by prevalent T > C and C > T
transitions with low to absent contribution of T > A, T > G, C > G, and C > A transversions (Figures 1
and 4). Notably, in addition to the predominance of C > T over T > C transitions, the ultra-mutated
case 12 GL also showed a significant proportion of C > A transversions (Figure 1), which presented
four peaks in correspondence of the trinucleotide contexts CCT, TCT, GCT, and ACT (Figure 2). This C
> A mutational pattern accompanied to prevalent C > T transitions corresponds to signature SBS14 in
the COSMIC database [21], which has been associated with the concurrent impairment of POLE and
MMR functions [22].
2.6. POLE and POLD1 Mutations
As POLE and POLD1 genes were missing from the TML assay, all samples were evaluated for
mutations in these two genes using a custom next-generation sequencing panel. A germline Arg742Cys
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(exon 20; rs768004570) mutation was detected in the polymerase domain of POLE of patient 12 GL.
This mutation was classified in the ClinVar database as of uncertain significance and annotated by
PolyPhen software (genetics.bwh.harvard.edu/pph/) as probably damaging (Supplementary Materials
Table S2).
2.7. Microsatellite Instability
Microsatellite instability (MSI) analysis was performed on all 16 samples comparing tumour
and normal profiles of six polyA microsatellite markers. Two cases scored positive, 5 GL showed
instability in 2/5 microsatellite markers (NR21, BAT26) and 12 GL in 4/5 microsatellites (NR21, NR24,
BAT25, BAT26). These two cases had truncating or missense pathogenic mutations in MSH2 and MSH6,
respectively (Supplementary Materials Table S2). The remaining 14 cases had stable microsatellites
including case 1 GL with a MLH1 missense mutation reported as benign in the PolyPhen database
(Supplementary Materials Table S2).
2.8. Immunohistochemical Analysis of Mismatch Repair Proteins
Three cases (1 GL, 5 GL, 12 GL) with mutations in MMR genes were immunostained for all four
MMR proteins. Neoplastic cells of cases 5 GL and 12 GL, which respectively harboured a double
mutation in MSH2 (GLy164Glu and Val684Ter) and a mutation in MSH6 (Glu1322Ter), showed loss of
the corresponding mutated protein (Figure 5) and positive staining for the other three proteins. Case 1
GL, harbouring the missense benign mutation in MLH1, had positive immunostaining for all four
MMR proteins.
2.9. Ultra-Mutated IDH-wt GBMs Featured High Content of Giant Cells, MMR Protein Loss, and MSI
Both ultra-mutated GBMs had at least 25% of giant cells at histopathology (Figure 4) and TP53
mutations and pathogenic mutations in MMR genes (MSH2 and MSH6); case 12 GL also had POLE
mutation. In addition, they had microsatellite instability as detected by MSI-PCR and MMR protein
loss of expression at immunohistochemistry.
2.10. Survival Analysis
Overall survival ranged between 3 and 79 months (median: 19 months; mean 25 months); 8 (50%)
subjects died of the disease during follow-up.
At univariate analysis for tumour-specific survival, we tested: mutation in TP53; mutation in
PTEN; amplification in EGFR; homozygous deletion in CDKN2A; presence of mutation in MMR genes
MSH2 and MSH6; presence of TML over 9 mutations/Mb. The only significant genomic alteration
associated with patients’ survival was TML over 9 mutations/Mb (p = 0.04; Figure 6).
2.11. Ultra-Mutated GBMs in the TCGA PanCancer Atlas
Search for GBMs in the TGCA PanCancer Atlas through cBioPortal [23,24] identified 266 cases
with available information on exome mutations and patients age. Of these, 80 patients were < 55 years
(14 IDH-mut and 66 IDH-wt), and 186 ≥ 55 years (2 IDH-mut and 184 IDH-wt). In these 266 GBMs,
mutations ranged from 16 to 12, 189 per exome. Eight cases could be considered hyper-mutated and
two ultra-mutated according to cut offs of ≥ 9 muts/Mb for hypermutation and > 100 muts/Mb for
ultra-mutation, as defined by Campbell et al. [20]. In fact, the eight hypermutated cases had ≥ 275
mutations per exome (range 275 to 1003) that correspond to > 9 muts/Mb, assuming that an exome is
1% of the genome, that is 30 × 106 bp. The two ultra-mutated cases had 6910 and 12,189 mutations that
correspond to > 200 muts/Mb.
Of the eight hypermutated GBMs, four were from patients < 55 years (4/80, 5%) and included three
IDH-wt- (377, 576, and 1003 mutations) and one IDH-mutated case (313 mutations), while four were
IDH-wt from patients ≥ 55 years (275, 284, 343, and 529 mutations). Among hyper-mutated GBMs,
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two cases had POLE mutations: an IDH-wt GBM from a 66 year old patient (TGCA-14-1795-01) which
had 343 mutations and POLE Asp1123Asn mutation with unknown significance; a giant cell IDH-wt
GBM from a 48 year old patient (case 19-1787-01) which had 576 mutations and POLE Ala399Val
mutation reported of uncertain significance in the ClinVar database. None of the hypermutated cases
had MMR mutations.
Only two cases were ultra-mutated and were IDH-wt from females aged 53 and 23 years,
respectively: TCGA-19-5956 with 6910 mutations and TCGA-06-5416 with 12,189 mutations. Both cases
harboured concomitant somatic mutations in POLE and MMR genes, namely, TCGA-19-5956 had two
POLE (Arg1826Trp; Ala456Pro) and one MLH1 (Arg265Cys) missense mutations; TCGA-06-5416 had a
POLE (Val411Leu), MSH2 (Lys871Asn), and MSH6 (Arg482Gln) missense mutations. Notably, case
TCGA-19-5956 had been classified as giant cell GBM and case TCGA-06-5416 histologically showed
multinucleated giant cells.
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Figure 4. Mutational signatures of 16 IDH-wt glioblastomas. The signatures of somatic mutations
(mutational spectrum) of individual tumours were obtained considering six major mutation classes: C
> T; C > A; C > G; T > A; T > C; T > G. On top are the two ultra-mutated samples with indications of
tumour mutational load (TML) and the peculiar molecular alterations. The mutational signature of case
12 GL shows a predominance of C > T over T > C transitions, and four peaks of C > A transversions
in the trinucleotide contexts CCT, TCT, GCT, and ACT; this latter mutational pattern corresponds to
signature SBS14 in the Catalogue Of Somatic Mutations In Cancer (COSMIC) version 3, and is associated
to tumours with concurrent impairment of DNA mismatch repair and POLE proofreading functions
(https://cancer.sanger.ac.uk/cosmic/signatures/SBS/) [25]. On the horizontal axis, the reference base with
5′ (left) and 3′ (right) bases are shown. On the vertical axis, the number of mutations is shown.
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TML > 200 mutations/Mb was associated with better prognosis in IDH wild-type GBMs (p-value = 0.036).
3. Discussion
The results of our study on IDH-wt GBMs of adults < 55 years may be summarized as follows:
(i) IDH-wt GBMs accounted for 14.8% (16/108) of GBMs of this age group; (ii) TML in these 16 cases
ranged between 5.66 and 219.79 mutations per megabase and, thus, 8 (50%) GBMs were hypermutated
(> 9 muts/MB) and two of those were ultra-mutated (> 100 muts/MB); (iii) 2 ultra- utate GBMs had
inactivating mutations in one MMR gene and MSI and they featured enrichment in gia t c lls; iv) on
ultra-mutated GBM h d also a germline POLE utation previously undescribed as pathogenic; v)
hyper-mutated GBMs had l nger lif expectancy.
The IDH-wt GBMs accou ted for about 15% of GBMs < 55 years in our hospital series and w re
charact rized by frequent TP53 and PTEN mutation, EGFR gene am lification, CDKN2A homozygous
deletion, gains of chromosome 7 nd losses of chromosomes 10 and 13. All these figures are in line
with those reported for IDH-wt GBMs [9–11,26–28].
As highlighted by Campbell et al., dissi ilar thresholds and methodologies and the lack of an
a reed definition of hypermutation are major is u in the study f TML [20]. To address these questions,
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they analysed TML in 78,452 adult and 2885 childhood cancers and established 9.9 and 9 muts/Mb
as cut-offs for hypermutation in childhood and adult cancers, respectively, and 100 muts/Mb as the
cut-off for ultra-mutation [20]. They also demonstrated excellent concordance among exome, genome,
and two separate targeted panel sequencing consisting of 315 and 884 genes covering 1.1 and 3.25 Mb,
respectively, for the assessment of hypermutation across different types of cancer [20]. By using those
cut off values, 8 out 16 IDH-wt newly diagnosed GBMs in our cohort had > 9 muts/Mb and should be
considered hypermutated; two of those had > 100 muts/Mb and should be classified as ultra-mutated.
The frequency of hyper- and ultra-mutated tumours in our cohort (50% and 12.5%, respectively)
was higher than that reported in other cohorts of GBMs [16,17] and that found in GBMs within the
TGCA PanCancer Atlas [20,21] However, it is in line with the high frequency of hypermutation in
brain tumours found by Campbell et al. [20] among all hypermutated and ultra-mutated neoplasms.
Difference with other studies may be due to the use of different methodologies in terms of analysed
genes and type of mutations considered. In addition, we may hypothesize that the high frequency of
ultra-mutated GBMs could depend on the selection criteria of our cohort (i.e., IDH-wt status and age
below 55 years). Indeed, a similar frequency (11%) of ultra-mutated cases was present among IDH-wt
high-grade gliomas from patients < 55 years old in the cohort of Erson-Omay et al. [29]. In addition,
two ultra-mutated GBMs found in the Glioblastoma Multiforme TGCA PanCancer Atlas were IDH-wt
and were from patients < 55 years of age.
It is known that different mutagenic processes give rise to different combinations of mutation types,
called signatures [30]. The mutational spectrum of our IDH-wt cohort was characterized by prevalent
T > C and C > T transitions. Accordingly, two ultra-mutated GBMs had a signature characterized by a
predominance of C > T over T > C transitions and low to absent contributions of T > A, T > G, and
C > G transversions signatures [30]. Interestingly, one of the cases also featured a high rate of C > A
transversions which presented four peaks in the trinucleotide contexts CCT, TCT, GCT, and ACT. This
mutational signature overlaps COSMIC signature SBS14, which has been associated with tumours
with concurrent impairments of POLE and MMR functions [21,22]. Fittingly, this GBM had MSI
associated to a somatic MSH6 mutation and a germline mutation in the polymerase domain of POLE.
This latter is the Arg742Cys substitution, which is reported as of uncertain significance in the ClinVar
database. It involves the polymerase domain of POLE, and not the proofreading exonuclease one,
different from POLE mutations which are commonly associated with hypermutation [19]. However,
the association of Arg742Cys substitution with the COSMIC SBS14 mutational signature strongly
suggests its pathogenicity [18]. Indeed, this signature is characteristic of tumours showing both MMR
deficiency and POLE loss of function [18]. In addition, Campbell et al. [20] recently reported POLE
driver mutations outside the exonuclease proofreading domain, suggesting that other domains might
be responsible for proofreading. Interestingly, Erson-Omay et al. previously reported six ultra-mutated
high-grade gliomas with a signature characterized by an increased proportion of C > A transversions
associated with somatic mutations in the POLE exonuclease domain and, in three cases, a germline
MSH6 mutation [21].
Hypermutation in cancer is associated with defective MMR and/or POLE functions [16,20].
In particular, isolated MMR deficiency and microsatellite instability have been mostly restricted
to hyper-mutated tumours (TML between 10 and 100 muts/Mb), while ultra-mutated tumours
(>100 muts/Mb) are microsatellite stable and POLE mutated. This study showed that hypermutation in
GBM is not a unique feature of tumours with MMR genetic alterations. Indeed, fourteen hypermutated
GBMs (six in our cohort and eight in the TGCA cohort) had no MMR mutations. In addition, it
demonstrated that ultra-mutation can also be found in GBMs with MSI and isolated MMR deficiency.
Indeed, one ultra-mutated GBM had MSH2 somatic mutation in the absence of POLE impairment.
Accordingly, an ultra-mutated GBM with MSH6 somatic mutation, but not POLE mutation, was
previously reported by Erson-Omay et al. [21]. In addition, MLH1 and MSH6 somatic mutations were
recently found in one primary and four recurrent IDH-wt GBMs [11].
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Erson-Omay et al. described a predominance of large and bizarre multinucleated giant cells
in ultra-mutated GBMs with POLE mutations and they concluded that “somatic POLE altered
ultra-mutated GBMs represent a subset of all giant cell GBM” [20]. In line with this observation,
two ultra-mutated GBMs with POLE mutation in the TGCA PanCancer Atlas were histologically
characterized by the presence of giant cells. However, both ultra-mutated GBMs in our cohort had
giant cell enrichment and none had somatic POLE mutation, but rather germline POLE mutation or
isolated MSH2 mutation. Besides, Vande Perre et al. recently reported POLE germline mutations
in two patients with giant cell GBM [31]. Therefore, this study suggests that ultra-mutated GBMs
might represent a subgroup of giant cell GBMs, which is not only characterized by POLE mutations.
However, giant cell enrichment is not a unique feature of ultra-mutated GBMs and no ultra-mutated
cases were found in a cohort of giant cell GBMs in a recent study [32].
Due to the small number of cases, we could not analyse whether there was a difference in
survival length between hyper- and ultra-mutated GBMs. Although our findings should be interpreted
with caution since multivariate survival analysis could not be performed due to the low number
of patients, the hyper-mutated (including the ultra-mutated) GBMs in our cohort had significantly
better prognosis than non-hypermutated tumours. Therefore, although IDH-wt GBMs are considered
to have bad prognosis [4–6], our findings suggest that hyper-mutated GBMs may represent a less
aggressive subgroup.
In addition to the prognostic significance, ultra-mutation in GBM might also have therapeutic
implications. Indeed, a report suggests that ultra-mutated paediatric GBMs with germline MMR
defects may have good response to immunotherapy [33]. Although limited data exist on the potential
clinical benefit of immunotherapy in GBM, the evidence that 12.5% of IDH-wt GBM in adults < 55
years are ultra-mutated may offer alternative therapeutic strategies in this age group.
4. Materials and Methods
4.1. Cases
A total of 16 (14.8%) IDH-wt GBMs with available follow-up data were found among 108 GBMs that
had been surgically resected from patients between 18 and 54 years at the Unit of Neurosurgery of the
Azienda Ospedaliera Universitaria “G. Martino” of Messina, Italy, between 2011 and 2018. In all cases,
macroscopically complete surgical removal was achieved. None of the patients received preoperative
therapy. All cases were formalin-fixed and paraffin-embedded (FFPE) for routine histological evaluation.
Histological diagnosis was confirmed by independent revision of two pathologists before inclusion in
the study. The IDH mutational status was firstly assessed by immunohistochemistry against IDH1
R132H, followed by IDH1/IDH2 sequencing in immuno-negative cases. The study was approved
by the Ethics Committee of the Azienda Ospedaliera Universitaria (A.O.U) Policlinico Gaetano (G.)
Martino (Messina, Italy) protocol number 47/19 of 2 May 2019. Informed consent was obtained from
each patient.
4.2. Mutational and Copy Number Variation Status of 409 Cancer Genes
For each case, DNA was obtained from FFPE tumour and from matched non-neoplastic brain
(surrounding the tumour that had been removed and showing no microscopic neoplastic infiltration)
using 10 consecutive 4 µm sections and the QIAamp DNA FFPE Tissue Kit (Qiagen) and qualified as
reported elsewhere [34]. The Oncomine Tumour Mutational Load (TML) panel with next-generation
sequencing assay (ThermoFisher) was used. The assay covers 1.65 Mb of genomic space and includes
all exons of 409 cancer-related genes.
Sequencing was performed on Ion Torrent platform using 20 ng of DNA for each multiplex PCR
amplification and subsequent library construction. The quality of the obtained libraries was evaluated
by the Agilent 2100 Bioanalyzer on-chip electrophoresis (Agilent Technologies). Emulsion PCR to
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clonally amplify the libraries was performed with the Ion OneTouch™ OT2 System (ThermoFisher).
Sequencing was run on the Ion Proton (ThermoFisher) loaded with Ion PI Chip v3.
Data analysis, including alignment to the hg19 human reference genome and variant calling,
was done using Torrent Suite Software v.5.10 (TermoFisher). Filtered variants were annotated using a
custom pipeline based on vcflib (https://github.com/ekg/vcflib), SnpSift [35], Variant Effect Predictor
(VEP) [36], and NCBI RefSeq database. Additionally, alignments were visually verified with the
Integrative Genomics Viewer (IGV) v. 2.3 [37] to further confirm the presence of identified mutations.
CNV was evaluated using OncoCNV v6.8 [38], comparing the BAM files obtained by sequencing
of tumour samples with those obtained from blood samples. The software includes a multi-factor
normalization and annotation technique enabling the detection of large copy number changes from
amplicon sequencing data and permits to visualize the output per chromosome.
4.3. Tumour Mutational Load and Mutational Signatures
Tumour mutational load (TML) and mutational spectrum for each sample were evaluated using
the Oncomine TML 5.10 plugin available on IonReporter software (ThermoFisher). Default modified
parameters were used according to the manufacturer’s protocol in order to exclude false positives
due to the sequencing artefacts. In detail, a threshold of at least 20 reads and an allelic frequency
of 10% of variant was used to perform mutation calling. In particular, TML was expressed as the
number of mutations per megabase (muts/Mb), where mutations include non-synonymous missense
and nonsense single nucleotide variants (SNVs), plus insertion and deletion variants (InDels) detected
per megabase (Mb) of exonic sequences.
The signatures of somatic mutations (mutational spectrum) of individual tumours were obtained
considering six major mutation classes: C > T (G:C > A:T); C > A (G:C > T:A); C > G (G:C > C:G);
T > A (A:T > T:A); T > C (A:T > G:C); T > G (A:T > C:G) [27,28]. Mutational Signatures in Cancer
(MuSiCa) software [39] was used to obtain specific signatures for each sample. The software used .vcf
files to align the sequences to the hg19 human reference genome using targeted sequencing parameters.
The different types of base-pair substitutions, comprising all non-synonymous missense and nonsense
SNVs were normalized per Mb of exonic sequence. The percentage of each group in each sample
was computed.
4.4. Mutational Analysis of POLE and POLD1 Genes
A next-generation DNA sequencing custom panel was designed to investigate the mutational
status of POLE and POLD1 genes, which are not included in the TML panel. Sequencing was performed
on Ion Torrent platform and data analysis was performed using the same pipeline used for TML panel.
4.5. Microsatellite Instability Analysis
MSI was tested by a fluorescent multiplex PCR exploiting the 5 mononucleotide microsatellites
BAT25, BAT26, NR21, NR22, and NR24 [13]. The obtained amplicons were separated by capillary
electrophoresis using the ABI Genetic Analyzer 3130XL platform (Applied Biosystems). Variations ≥
3bp for BAT-25, NR21, and NR22 and ≥ 4bp for BAT-26 were considered as unstable.
4.6. Immunohistochemistry of DNA Mismatch Repair Proteins
Immunostaining was performed using the Bond Polymer Refine Detection kit (Leica Biosystems)
in a BOND-MAX system (Leica Biosystems) on 4 µm thick FFPE sections using the following primary
antibodies purchased from DakoCytomation: mouse monoclonal clone ES05 against MLH1 at working
dilution 1:30 and clone FE11 against MSH2 at working dilution 1:30; rabbit monoclonal clone EP49
against MSH6 at working dilution 1:100, and clone EP51 against PMS2 at working dilution 1:100.
Normal cells within the samples were used as positive internal controls.
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4.7. Statistical Analysis
Overall survival was assessed by the Kaplan–Meier method, using the date of surgery as the
entry data and length of survival until the patient’s death as the endpoint. Patients who died of
diseases independent from GBM were censored. The Mantel–Cox log-rank test was applied to assess
the strength of association between disease-specific survival and molecular alterations as a single
variable. A p-value < 0.05 was considered as significant. All analyses were performed using MedCalc
for Windows version 15.6 (MedCalc Software, Ostend, Belgium) and R v. 3.2.1
5. Conclusions
This study identified a molecular subgroup of ultra-mutated IDH-wt GBMs in adults < 55 years,
which was characterized histologically by the presence of at least 25% homogenously dispersed giant
cells. Ultra-mutation and giant cells were not only associated with POLE mutations, but also with
isolated defective MMR. Although this study has the limitation of a relatively low number of cases, it
opens the perspective to potentially include these patients in immunotherapy clinical trials.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/9/1279/s1,
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